

Drug Utilization Review (DUR) Meeting Minutes
March 2, 2009

Members Present: Patricia Churchill, Norman Byers, Carrie Sorenson, Greg Pfister, Steve Irsfeld, Kim Krohn, Jeffrey Hostetter, John Savageau, Scott Setzepfandt, Leeann Ness, Carlotta McCleary, Cheryl Huber and Todd Twogood.

Members Absent: Gary Betting

Medicaid Pharmacy Department: Brendan Joyce

HID Staff Present: Candace Rieth

Chair, C. Sorenson called the meeting to order at 1:09 pm. Chair, C. Sorenson asked for a motion to approve the minutes from the December meeting. N. Byers moved that the minutes be approved and J. Hostetter seconded the motion. Chair, C. Sorenson called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update

B. Joyce stated that the budget information is going through the legislative process and that he will update the Board at the next meeting.

Tablet Splitting Initiative

Previously, the Board voted to implement a tablet splitting initiative with continuous updates from the State. The State is interested in adding Lipitor and Lexapro to the list of medications that can be split. An educational endeavor, including provider mailings and newsletters will occur prior to implementation.

Yearly PA Review

The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Antihistamines, PPIs, COX-II/NSAIDs, Revatio, Actoplus met, and Azasite/Quixin were reviewed. The following recommendation were made: change the wording of the forms from 'physician' to 'prescriber' to include prescriptions written by nurse practitioners, make the medications listed on the Ophthalmic PA form the same as the medications listed on the Ophthalmic PA Criteria form and to include omeprazole on the PPI criteria form.

Legislative Update

B. Joyce gave a legislative update on HB 1385. The committee reviewing the exempt drug classes from prior authorization received a copy of the DUR Board's recommendations regarding those classes. A vote was taken in the house to maintain the exempt status of these classes. Outcomes of the Senate vote will be presented at the June meeting.

Strattera and Stimulants

The board reviewed patients receiving concurrent prescriptions of Strattera and stimulants. A recommendation was made to limit the initial day's supply of stimulants to decrease waste and increase compliance. The Board would like the State to move forward with an educational endeavor prior to implementation of initial fill quantity limits on stimulants.

Aczone Review

B. Joyce reviewed Aczone with Board members. There was no public comment. N. Byers made a motion to prior authorize Aczone. J. Savageau seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. N. Byers moved to approve the new criteria and C. Huber seconded the motion. Chair, C. Sorenson called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held June 1, 2009. J. Hostetter made a motion to adjourn the meeting and K. Krohn seconded. Chair C. Sorenson adjourned the meeting at 2:10 pm.